SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

BeyondSpring Inc. (BYSI) News

Follow BeyondSpring Inc. (BYSI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol BYSI Asset equity Sector Markets 90 days 4 Last 0.4748 Updated Sep 29, 2026, 11:13 AM UTC Open live news feed Open BYSI chart & news
L BeyondSpring Unveils Bulin Collaboration Via Subsidiary Sale; Sets ATM for Up to 9.2M Shares BeyondSpring announced two material agreements: a strategic Share Purchase and Collaboration Agreement tied to the China portion of the DUBLIN-4 Phase 3 trial, and a new at-the-market equity program. The company will tra GEOPOLITICS | Sep 29, 2026, 11:13 AM UTC L Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares Beyondspring Inc NASDAQ:BYSI EQUITY | Sep 29, 2026, 11:09 AM UTC L BeyondSpring Inc. (BYSI) Gets FDA Fast Track; Sells China Sub for DUBLIN-4 Support BeyondSpring received FDA Fast Track for plinabulin plus docetaxel in post-ICI non-squamous NSCLC and agreed to sell its Chinese subsidiary to Biolin, which will fund China enrollment for the global Phase 3 DUBLIN-4 tria GEOPOLITICS | Sep 29, 2026, 11:09 AM UTC M BeyondSpring FDA Fast Track for plinabulin in post-ICI NSCLC BeyondSpring announces the FDA granted Fast Track designation for plinabulin in post-ICI non-squamous NSCLC, and the company describes a strategic transaction to advance its global Phase 3 DUBLIN-4 trial toward a planned REGULATION | Sep 29, 2026, 11:08 AM UTC L BeyondSpring (BYSI) reports Q2 2026 financial results, corporate update BeyondSpring (BYSI) reports its second-quarter 2026 financial results and provides a corporate update, according to a TradeXchange Newsdesk alert. EARNINGS | Aug 14, 2026, 09:15 PM UTC M BYSI unit SEED Therapeutics gets FDA orphan drug designation for ST-01156 BeyondSpring’s subsidiary SEED Therapeutics receives FDA orphan drug designation for ST-01156, a small molecule degrader of RNA-binding motif protein 39, for neuroblastoma. REGULATION | Aug 13, 2026, 03:50 PM UTC